en · de · es · fr · pt
sr9009-notes.peptides9000.com › Data › Background And Mechanism — Beginner to Advanced

Background And Mechanism — Beginner to Advanced

By Editorial Desk · published 2025-08-13 · last reviewed 2025-10-04 · Data

circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-10-04. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

SR9009 Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

Background and Mechanism of SR9009

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Related pages on this site

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Supporting material

=== SEIR model === For many important infections, there is a significant latency period during which individuals have been infected but are not yet infectious themselves. During this period the individual is in compartment E (for exposed).

The Unitized Group Ration – Express (UGR-E or UGR-Express), nicknamed the "kitchen in a carton", consists of meals in self-heating steam table trays based on the UGR-H&S meal offerings. The UGR-E is designed to provide hot meals where feeding a group with hot food would otherwise be unfeasible. Unlike other UGRs, it uses a flameless ration heater and does not require a separate field kitchen. The UGR-E begins heating with the pull of a tab, and can fully heat a meal within 30 to 45 minutes. The UGR-E has 4 breakfast menus, 8 lunch/dinner menus, and 1 holiday menu. Each meal provides an average of 1,300 kcal. Each UGR-E module contains 18 meals, with each pallet holding 400 meals. UGR-E modules have a minimum shelf life of 18 months at 80 °F (26.6 °C).

In other systems considered non-traditional, droplet-based microfluidic system, magnetic microdroplets can be a facile means of fabrication and control of micro and nanomaterials, sometimes called "robots". These nanostructures are formed of magnetic nanoparticles in microdroplets that have been manipulated into specific structures by an applied magnetic field. Microhelices are a multifunctional application of this technology. Monodisperse droplets containing magnetic nanoparticles are generated and subjected to a magnetic field which organizes the nanoparticles into a helical template that is fabricated in place through photoinduced polymerization. These microhelices were shown to be effective at clearing channels that were blocked with semi-solid composites of fats, oils, and proteins, such as those found in arteries. Microhelices and microparticle clusters in magnetic droplets have been demonstrated to be a means of transport for small (500 μm diameter) microparticles, showing applications in drug delivery as well. Non-spherical microstructures have also been fabricated using magnetic microfluidics, demonstrating the minute control that is available. Among the non-spherical microstructures to be fabricated were graphene oxide microcapsules that could be aspirated and reinflated using a micropipette, while also exhibiting photoresponsive and magnetoresponsive behavior.

Sources: en.wikipedia.org

Supporting material

== Measurement == All the major indicators mentioned in the table are numerically measurable in a laboratory or otherwise but, for many, high values are also injurious to health just as are low values. This affects the exact measurement of positive health. The optimal levels of most of these parameters are not known – thus a scale to exactly measure the level of positive health of a person is yet to be developed. However, there are parameters such as endorphins, semen quality in men, FEV1/FVC ratio, oxygen saturation, bone density, P3 amplitude, and handGrip strength whose increased value progressively indicates a better positive health.

==== Efp ==== Efp, or estrogen-inducible RING-finger protein, is an E3 ubiquitin ligase whose overexpression has been shown to be the major cause of estrogen-independent breast cancer. Efp's substrate is 14-3-3 protein which negatively regulates cell cycle.

On December 10, 2010, Sanders delivered an 8-hour and 34-minute speech against the Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010, which proposed extending the Bush-era tax rates. He argued that the legislation would favor the wealthiest Americans. "Enough is enough! ... How many homes can you own?" he asked. Nevertheless, the bill passed the Senate with a strong majority and was signed into law a week later. In February 2011, Nation Books published the speech as The Speech: A Historic Filibuster on Corporate Greed and the Decline of Our Middle Class, with authorial proceeds going to Vermont nonprofit charitable organizations. In 2016, Sanders voted for the Federal Reserve Transparency Act, which included proposals for a reformed audit of the Federal Reserve System.

== Technique == The technique initially incubates a small amount of abnormal prion with an excess of normal protein, so that some conversion takes place. The growing chain of misfolded protein is then blasted with ultrasound, breaking it down into smaller chains and so rapidly increasing the amount of abnormal protein available to cause conversions. By repeating the cycle, the mass of normal protein is rapidly changed into the prion being tested for.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

Network